Journal
CANADIAN JOURNAL OF CARDIOLOGY
Volume 31, Issue 10, Pages 1293-1302Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cjca.2015.03.023
Keywords
-
Categories
Funding
- Novo Nordisk Foundation
Ask authors/readers for more resources
The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available